Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807675 | 1.00 | MTNR1A (0.46) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL839817 | 0.89 | SCN9A (0.54) | MTNR1AMTNR1BBRAFSCN5ASCN9A | |
| SCHEMBL841202 | 0.85 | SCN9A (0.55) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL7031626 | 0.80 | KCNH2 (0.56) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL4788640 | 0.80 | KCNH2 (0.56) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL7031622 | 0.80 | KCNH2 (0.56) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL839801 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL4786804 | 0.78 | MTNR1A (0.55) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL4788623 | 0.74 | DRD2 (0.56) | MTNR1AMTNR1BDRD2DRD3HTR1D | |
| SCHEMBL4786508 | 0.74 | DRD2 (0.56) | MTNR1AMTNR1BDRD2DRD3HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | claimed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | claimed |
| EP-2158198-B1 | N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | MTNR1A 191/4885MTNR1B 271/4885DRD2 2083/4885 |
| US-20120238579-A1 | New Compounds 806 | CYP2B6, CYP11B2, NDUFS6 | MTNR1A 1614/4885MTNR1B 943/4885DRD2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.